Global Wilson’s Disease Market - Industry Trends and Forecast to 2028

Market Analysis and Insights: Global Wilson’s Disease Market

The Wilson’s disease market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 6.2% in the above-mentioned research forecast period. Increase in research advancement and different initiatives taken by the market players are some of the drivers for the Wilson’s disease market growth.  

Wilson’s disease is a genetic disorder which is characterized by the accumulation of excessive copper in liver or brain. The disease is caused due to the mutations in the ATP7B gene. The healthy patients after consuming the copper excrete out the extra copper but patients suffering from WD does not secrete and they can accumulated. Most people with Wilson’s disease are diagnosed between 5 and 35 years of age but it can also affect younger and older people. Different symptoms of WD are abdominal swelling, pain, jaundice and blood vomiting. Symptoms that appear lately are psychiatric, hepatitis or neurological symptoms. The patients find difficulty in various activities such as talking, swallowing and walking. They also suffer from mental illness such as aggression, depression or suicidal thoughts. Women suffering from WD led to irregular mensuration or infertility and miscarriage. Therefore, early diagnosis and treatment for WD is very important in order to avoid the life-threatening symptoms. Kayser-Fleischer rings are another symptom for the WD patients. Kayser-Fleischer rings in which golden to greenish-brown rings formed in the iris shows that there is a deposition of copper in the periphery of the cornea. Patients with hepatic symptoms (65%) and neurological signs (95%) show K-F rings. Copper chelation medications are used for the therapy of K-F rings. For instance, the novel therapy for the treatment of WD is WTX101 (bis-choline tetrathiomolybdate) which is the copper protein binding agent and is under phase III trial. The dosage form for the agent is in the form of oral enteric coated tablet whose strength is 15mg. The motive behind the study was to check and evaluate the efficacy of the drug in 18 years and older WD patients for 48 weeks as compared with the standard of care (SOC).

Increasing the implementation of patient assistance programme, the technological advancements that allow early detection and increasing awareness of Wilson's disease are expected to fuel the Wilson's disease market. However, high treatment costs due to complications and less awareness among people about the symptoms of Wilson’s disease are some factors hampering the growth of the Wilson’s disease market.

Increase in healthcare expenditure and government support is acting as the opportunity for the Wilson's disease market, in addition, initiatives taken by the countries to work on the diagnosis and treatment for WD patients enhance the Wilson's disease market growth. For instance, the project “WILSONINDIA” which work on the diagnosis and treatment of WD includes the novel treatment such as cell models, DNA chip-based diagnosis and adult stem cell-based therapy of liver disease. There is research collaboration between EU and India. The challenging factors for the WD are the longer delay between the first symptoms of WD to the diagnosis that is early diagnosis of the WD and is one of the challenges for the healthcare professionals in the Wilson's disease market.

This Wilson’s disease market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the Wilson’s disease market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Wilson’s Disease Market Scope and Market Size

The Wilson’s disease market is segmented on the basis of patient population, tests type, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of patient population, the Wilson’s disease market is segmented into symptomatic Wilson disease, asymptomatic Wilson disease and during pregnancy.
• On the basis of tests type, the Wilson’s disease market is segmented into blood and urine test, eye exam, liver biopsy, imaging test and genetic testing.
• On the basis of treatment, the Wilson’s disease market is segmented into medication and surgery. Medication is further segmented to copper chelating medications, zinc supplements and vitamin B6. Copper chelating medications is further segmented to dimercaprol, penicillamine, dimercaptopropane sulfonate and trientine.
• On the basis of route of administration, the Wilson’s disease market is segmented into oral, parenteral and others.
• On the basis of end-users, the Wilson’s disease market is segmented into hospitals, specialty clinics and others
• On the basis of distribution channel, the Wilson’s disease market is segmented into hospital pharmacy, retail pharmacy and others.

Global Wilson’s Disease Market Country Level Analysis

Global Wilson’s disease market is analysed and market size information is provided by country, patient population, tests type, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the wilson’s disease market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, Asia-Pacific especially in India and China accounts the largest market share due to increase in medical tourism in developing countries and initiatives taken by the market players. North America has the second largest market share due to increase in health awareness about treating Wilson's disease. Europe also holds the market share due to increase in aging population.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The Wilson’s disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to Wilson’s disease market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the Wilson’s disease market in the growth period.

Competitive Landscape and Wilson’s Disease Market Share Analysis

The Wilson’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Wilson’s disease market.

The major players covered in the Wilson’s disease market report are Valeant Pharmaceuticals International, Inc., Meda Pharmaceuticals, Inc., Teva Pharmaceuticals, Taj Pharmaceutical Limited, Ipsen Pharma, Wilson Therapeutics, Nobelpharma Co., Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-60056